论文部分内容阅读
选择两种具有协同免疫调节作用的细胞因子进行联合基因治疗是提高肿瘤细胞因子基因治疗的有效途径之一.目前对IL-2/TNF-α联合基因方案,特别是瘤体内注射途径的抗肿瘤研究尚未见报道.IL-2与TNF-α具有协同作用.因此我们分别将携带TNF-α基因和IL-2基因的腺病毒(Ad-TNF,Ad-IL-2)联合或直接注射于BALB/c小鼠肝癌内,观察其抗瘤效果,并探讨其抗肿瘤免疫机制.结果表明:1.TNF治疗组脾细胞NK、LAK、CTL活性及Mφ杀伤活性明显高于对照组,诱生的细胞因子包括IL-2、GM-CSF、IFN-γ、TNF和IL-
Selecting two kinds of cytokines with synergistic immunoregulation to perform combined gene therapy is one of the effective ways to improve the gene therapy of tumor cytokines. Currently the anti-tumor of IL-2/TNF-α combined gene program, especially intratumoral injection route Studies have not yet been reported. IL-2 and TNF-α have a synergistic effect. Therefore, we combined the adenovirus carrying the TNF-α gene and the IL-2 gene (Ad-TNF, Ad-IL-2) or injected directly into BALB. In mice with hepatocellular carcinoma, the anti-tumor effect was observed and its anti-tumor immune mechanism was explored. The results showed that: 1. NK, LAK, CTL activity and Mφ killing activity of spleen cells in TNF-treated group were significantly higher than those in the control group. Cytokines include IL-2, GM-CSF, IFN-γ, TNF, and IL-